153710 — Optipharm Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩78bn
- KR₩74bn
- KR₩17bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 13,653 | 13,046 | 14,258 | 16,008 | 17,373 |
Cost of Revenue | |||||
Gross Profit | 4,502 | 3,509 | 3,738 | 3,717 | 4,197 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 14,844 | 16,499 | 18,763 | 19,385 | 20,004 |
Operating Profit | -1,191 | -3,454 | -4,505 | -3,377 | -2,631 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -655 | -2,352 | -3,080 | -2,045 | -2,437 |
Provision for Income Taxes | |||||
Net Income After Taxes | -655 | -2,352 | -3,080 | -2,045 | -2,437 |
Net Income Before Extraordinary Items | |||||
Net Income | -655 | -2,352 | -3,080 | -2,045 | -2,437 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -655 | -2,352 | -3,080 | -2,045 | -2,437 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -45.3 | -164 | -211 | -140 | -166 |
Dividends per Share |